These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Reduction of the ring size of radiolabeled lactam bridge-cyclized alpha-MSH peptide, resulting in enhanced melanoma uptake.
    Author: Guo H, Yang J, Gallazzi F, Miao Y.
    Journal: J Nucl Med; 2010 Mar; 51(3):418-26. PubMed ID: 20150256.
    Abstract:
    UNLABELLED: The purpose of this study was to examine the profound effect of the ring size of the radiolabeled lactam bridge-cyclized alpha-melanocyte-stimulating hormone (alpha-MSH) peptide on its melanoma-targeting properties. METHODS: A novel cyclic alpha-MSH peptide, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-CONH(2) (DOTA-Nle-CycMSH(hex)), was synthesized and radiolabeled with (111)In. The melanocortin-1 receptor-binding affinity of DOTA-Nle-CycMSH(hex) was determined in B16/F1 melanoma cells. The internalization and efflux of (111)In-DOTA-Nle-CycMSH(hex) were examined in B16/F1 cells. The melanoma-targeting properties and SPECT/CT characteristics of (111)In-DOTA-Nle-CycMSH(hex) were determined in B16/F1 melanoma-bearing C57 mice. RESULTS: DOTA-Nle-CycMSH(hex) displayed 1.77 nM receptor-binding affinity. (111)In-DOTA-Nle-CycMSH(hex) exhibited rapid internalization and extended retention in B16/F1 cells. The tumor uptake of (111)In-DOTA-Nle-CycMSH(hex) was 24.94% +/- 4.58% and 10.53% +/- 1.11% injected dose per gram at 0.5 and 24 h after injection, respectively. Greater than 82% of the injected radioactivity was cleared through the urinary system by 2 h after injection. The tumor-to-kidney uptake ratios reached 2.04 and 1.70 at 2 and 4 h after injection, respectively. Flank melanoma tumors were clearly visualized by SPECT/CT using (111)In-DOTA-Nle-CycMSH(hex) as an imaging probe at 2 and 24 h after injection. The radioactivity accumulation in normal organs, except for the kidneys, was low at 2, 4, and 24 h after injection. CONCLUSION: The reduction of the peptide ring size dramatically increased the melanoma uptake and decreased the renal uptake of (111)In-DOTA-Nle-CycMSH(hex), providing a new insight into the design of a novel radiolabeled lactam bridge-cyclized alpha-MSH peptide for melanoma imaging and treatment.
    [Abstract] [Full Text] [Related] [New Search]